- Home
- NODK vs YMAB Comparison
NODK vs YMAB Comparison
Compare NODK & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- YMAB
- Stock Information
- Founded
- NODK 1946
- YMAB 2015
- Country
- NODK United States
- YMAB United States
- Employees
- NODK N/A
- YMAB N/A
- Industry
- NODK Property-Casualty Insurers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- YMAB Health Care
- Exchange
- NODK Nasdaq
- YMAB Nasdaq
- Market Cap
- NODK 290.9M
- YMAB 270.5M
- IPO Year
- NODK 2017
- YMAB 2018
- Fundamental
- Price
- NODK $14.10
- YMAB $4.95
- Analyst Decision
- NODK
- YMAB Buy
- Analyst Count
- NODK 0
- YMAB 11
- Target Price
- NODK N/A
- YMAB $19.64
- AVG Volume (30 Days)
- NODK 19.8K
- YMAB 333.1K
- Earning Date
- NODK 03-07-2025
- YMAB 03-04-2025
- Dividend Yield
- NODK N/A
- YMAB N/A
- EPS Growth
- NODK N/A
- YMAB N/A
- EPS
- NODK N/A
- YMAB N/A
- Revenue
- NODK $325,204,000.00
- YMAB $87,685,000.00
- Revenue This Year
- NODK N/A
- YMAB $20.07
- Revenue Next Year
- NODK N/A
- YMAB $8.76
- P/E Ratio
- NODK $45.52
- YMAB N/A
- Revenue Growth
- NODK 6.97
- YMAB 3.38
- 52 Week Low
- NODK $13.47
- YMAB $4.25
- 52 Week High
- NODK $17.24
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- NODK 45.41
- YMAB 39.96
- Support Level
- NODK $13.91
- YMAB $4.45
- Resistance Level
- NODK $14.30
- YMAB $4.97
- Average True Range (ATR)
- NODK 0.34
- YMAB 0.35
- MACD
- NODK 0.02
- YMAB 0.05
- Stochastic Oscillator
- NODK 29.82
- YMAB 55.45
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.